AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.

We believe that OMIC technologies represent an important first step towards gaining biological insights into:

  • How drugs work, giving them added value, reducing attrition rates and advancing  through the clinic.
  • Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.

latest news and events


May 2018

AROMICS to participate at the Genesis Drug Discovery meeting in Barcelona 10-11 May 2018

Dr.Carmen Plasencia, CEO of AROMICS one of the speakers on the 2nd Genesis...

mas noticias


April 2018

Berberine derivatives are present at IX WDD-2018 Congress

Dr. Paolo Lombardi, CEO of Naxospharma and former collaborator of AROMICS will present the advances...

mas noticias


With 35,000 genes and hundreds of thousands of protein states to identify, correlate, and characterize, the studies of one gene, gene product, or process are no longer reliable or cost-effective. We have entered the "omic" era in biology. But large- scale omic studies of cellular molecules in aggregate rarely answer interesting questions without the assistance of information from traditional hypothesis- driven research. These scientific methods are complementary and synergistic.

John N. Weinstein. Disease Markers 17(2): 77- 88, 2001.